Jianmin Pharmaceutical Group Co., Ltd. (600976) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Jianmin Pharmaceutical Group Co., Ltd.

Why is Jianmin Pharmaceutical Group Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 14.21%

The company has been able to generate a Return on Capital Employed (avg) of 14.21% signifying low profitability per unit of total capital (equity and debt)

The company is Net-Debt Free

Poor long term growth as Net Sales has grown by an annual rate of 3.24% and Operating profit at 22.88% over the last 5 years
The company is Net-Debt Free
The company has been able to generate a Return on Equity (avg) of 18.68% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of 3.24% and Operating profit at 22.88% over the last 5 years

Flat results in Jun 26

INTEREST(9M) At CNY 9.53 MM has Grown at 9.68%
ROCE(HY) Lowest at 12.14%
INVENTORY TURNOVER RATIO(HY) Lowest at 4.34 times

With ROE of 11.95%, it has a attractive valuation with a 1.45 Price to Book Value

Over the past year, while the stock has generated a return of -33.37%, its profits have fallen by -7.2%
At the current price, the company has a high dividend yield of 3.5

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Jianmin Pharmaceutical Group Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jianmin Pharmaceutical Group Co., Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Jianmin Pharmaceutical Group Co., Ltd.

-100.0%

-1.86

30.27%

China Shanghai Composite

0.9%

0.22

14.72%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.24%

EBIT Growth (5y)

22.88%

EBIT to Interest (avg)

40.51

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.36

Sales to Capital Employed (avg)

1.30

Tax Ratio

7.61%

Dividend Payout Ratio

38.37%

Pledged Shares

Institutional Holding

ROCE (avg)

15.07%

ROE (avg)

18.68%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.45

EV to EBIT

13.69

EV to EBITDA

10.96

EV to Capital Employed

1.69

EV to Sales

0.89

PEG Ratio

Dividend Yield

3.48%

ROCE (Latest)

12.38%

ROE (Latest)

11.95%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at -36.96 %

INTEREST COVERAGE RATIO(Q)

Highest at 5,042.73

CASH AND EQV(HY)

Highest at CNY 2,433.32 MM

OPERATING PROFIT(Q)

Highest at CNY 99.75 MM

OPERATING PROFIT MARGIN(Q)

Highest at 13.51 %

PRE-TAX PROFIT(Q)

Highest at CNY 81.46 MM

-11What is not working for the Company

INTEREST(9M)

At CNY 9.53 MM has Grown at 9.68%

ROCE(HY)

Lowest at 12.14%

INVENTORY TURNOVER RATIO(HY)

Lowest at 4.34 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.67 times

NET SALES(Q)

Lowest at CNY 738.07 MM

Here's what is working for Jianmin Pharmaceutical Group Co., Ltd.

Interest Coverage Ratio

Highest at 5,042.73

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Debt-Equity Ratio

Lowest at -36.96 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Operating Profit

Highest at CNY 99.75 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Operating Profit Margin

Highest at 13.51 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at CNY 81.46 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Cash and Eqv

Highest at CNY 2,433.32 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Jianmin Pharmaceutical Group Co., Ltd.

Net Sales

At CNY 738.07 MM has Fallen at -11.9%

over average net sales of the previous four periods of CNY 837.72 MM

MOJO Watch

Near term sales trend is very negative

Net Sales (CNY MM)

Interest

At CNY 9.53 MM has Grown at 9.68%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

Lowest at CNY 738.07 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Inventory Turnover Ratio

Lowest at 4.34 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 2.67 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Footer loading